Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06137300
NA

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Sponsor: Yi Yang

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.

Official title: Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke:a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

986

Start Date

2024-03-15

Completion Date

2027-12-31

Last Updated

2024-02-28

Healthy Volunteers

No

Interventions

DRUG

Urinary kallidinogenase for injection

Urinary kallidinogenase 0.15PNA once daily for 7 days.

OTHER

Guideline-prescribed medical therapy

Guideline-prescribed medical therapy

Locations (1)

First Hospital of Jilin University

Changchun, Jilin, China